



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/517,338  
Applicant : WARNAAR et al  
Filed : December 9, 2004  
TC/A.U. : 1642  
Examiner : Catherine M. Joyce

Docket No. : 2923-672  
Customer No. : 06449  
Confirmation No. : 2944

**DECLARATION**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

I, Stefan Ullrich, declare as follows:

1. That Stefan Ullrich and Sven Warnaar are the inventors of the subject matter described and claimed in the United States Patent Application Serial No. 10/517,338, filed on December 9, 2004, entitled "Co-administration of CG250 and IL-2 or IFN- $\alpha$  for Treating Cancer Such As Renal Cell Carcinomas".

2. That I am a co-author of an article entitled "A Phase I/II Trial with Monoclonal Antibody WX-250 in Combination with Low Dose Interleukin-2 in Metastatic Renal Cell Carcinoma", *Proceedings of the American Association for Cancer Research*, vol. 43, March 2002.

3. That I, Stefan Ullrich, am an inventor of the subject matter disclosed in this publication and co-inventor of the subject matter disclosed and claimed in the present application.



4. That in addition to myself, Stefan Ullrich, there are three other co-authors of the above publication: Joachim Beck, Carola Mala and Peter Mulders. While each of these individuals are co-authors of the publication, they are not co-inventors of the subject matter described therein.

5. That Joachim Beck and Peter Mulders are not inventors of the subject matter described in the above publication, but were listed as co-authors of the publication because they both were involved as control physicians surveying the Phase I/II Trial study.

6. That Carola Mala is not an inventor of the subject matter described in the above publication, but was listed as a co-author of the publication because she was involved the coordination and monitoring of the Phase I/II Trial study.

7. The undersigned further declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

by

  
Stefan Ullrich

*Feb 15, 2007*

Date